#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Epileptic encephalopathy Hereditary motor and sensory neuropathy Indolent systemic mastocytosis Fabry's disease Hodgkin's disease recurrent Splenic marginal zone lymphoma Pulmonary hypertension Leber's congenital amaurosis Amyloidosis Pyruvate dehydrogenase complex deficiency Neuroendocrine tumour Arginase deficiency Hepatic angiosarcoma Osteosarcoma Castleman's disease More trials…

    Learn about Rare Diseases

    Primary mediastinal large B-cell lymphoma – Treatment Prader-Willi syndrome Factor VIII deficiency – Diagnostics Bronchiolitis obliterans syndrome – Trials in Disease KBG syndrome – Life with Disease Prader-Willi syndrome – Basic Information X-linked lymphoproliferative syndrome – Trials in Disease Toxic epidermal necrolysis – Trials in Disease Alagille syndrome – Diagnostics Friedreich’s ataxia – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ezetimibe OMEGA-3-ACID ETHYL ESTERS 90 Alendronate Sodium Monohydrate Ampicillin Adenosine INCB123667 Escitalopram Oxalate Prasinezumab Fingolimod Hydrochloride Triamcinolone Acetonide Kyv-101 Alirocumab Florquinitau (18F) Fusidic Acid ABY-271 Epinephrine Pilocarpine Nitrate Lovo-B Purified Egg Phospholipids Nmd670 More therapies…

    Learn about Your Condition

    Craniopharyngioma Neurofibromatosis Hypoalbuminaemia Brain neoplasm Peyronie's disease Ewing's sarcoma metastatic Methylmalonic acidaemia Nicotine dependence Low cardiac output syndrome Pharyngeal cancer stage II Pharyngeal cancer stage I Malignant peritoneal neoplasm Pneumococcal infection Lymphangioleiomyomatosis Hepatitis B More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Mental Disorders

  • Study of psilocybin compared to personalized rTMS treatment in adults with treatment-resistant depression

    Recruiting

    2 1
    Investigated Diseases:
    • Depression
    Investigated Drugs:
    • Dry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol
    Italy

  • Safety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder

    Recruiting

    3 1 1
    Investigated Diseases:
    • Major depression
    Investigated Drugs:
    • 9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
    Belgium Bulgaria Croatia Czechia Estonia Finland +10

  • Study of deupsilocin besilate (CYB003) in adults with major depressive disorder comparing two doses against placebo

    Recruiting

    3 1
    Investigated Diseases:
    • Major depression
    Czechia Germany Greece Ireland Poland

  • Study of NBI-1065845 as add-on treatment to prevent depression relapse in adults with Major Depressive Disorder who responded to initial treatment

    Recruiting

    3 1
    Investigated Diseases:
    • Major depression
    Investigated Drugs:
    • 9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
    Bulgaria Estonia Italy Poland Spain

  • Long-term safety and effectiveness study of CYB003 (deupsilocin besilate) with optional additional doses for people with Major Depressive Disorder

    Recruiting

    3 1 1
    Czechia Germany Greece Ireland Poland

  • Evaluating NBI-1065845 as an Additional Treatment for Adults with Major Depressive Disorder Who Are Not Responding Adequately to Current Therapy

    Recruiting

    3 1
    Investigated Diseases:
    • Major depression
    Investigated Drugs:
    • 9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
    Belgium Finland Hungary Latvia
Previous Page
1 … 4 5 6 7 8 … 40
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!